Article

FDA's $6.4 Billion Plan for Quick Reviews Moves to Senate

Mylan Inc.

(MYL)

Pfizer Inc. (PFE)

A $6.4 billion effort to speed U.S. reviews of new drugs and medical devices is a step closer to law as the agreements , and other companies struck with regulators wind through Congress.

The Senate is set to begin voting as soon as today on more than $2 billion in new fees that drug and device companies will pay regulators through 2017 to review products for safety and efficacy. The figure includes $1.56 billion from generic-drug companies such as Canonsburg, Pennsylvania-based Mylan, which had been exempt from such fees.

Read the full story: http://hcp.lv/MB3OCO

Source: Bloomberg

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Martin Engelke
David Awad, PharmD, BCOP
Dr Adela Perolla
Dr Adela Perolla | Image Credit: - stock.adobe.com
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
4 experts are featured in this series.
2 experts in this video
Dr Ola Landgren
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo